Quark Biotech buys Incyte microarray assets

July 19, 2002 — Quark Biotech Inc., a Cleveland-based drug discovery company, has acquired Incyte Genomics’ microarray facility assets in order to beef up its high throughput functional screening, target validation and chemical sensing abilities.

With the deal, Quark hired the management and key personnel who operated the Incyte facility. Financial terms of the transaction were not disclosed.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.